Neuroendocrine prostate cancer treated with multimodal examination and therapy: A case report
Neuroendocrine prostate cancer (NEPC) is rare, with short overall survival, and no established standard therapy. Therefore, the management of NEPC is often challenging. We report a case of a 63-year-old male diagnosed with NEPC and treated with multimodal examinations and therapies. Chemotherapy of...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-09-01
|
| Series: | Urology Case Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S221444202200170X |
| _version_ | 1811309225904701440 |
|---|---|
| author | Midori Hara Satoru Kira Manabu Kamiyama Tatsuya Ihara Takeshi Sato Takahiko Mitsui |
| author_facet | Midori Hara Satoru Kira Manabu Kamiyama Tatsuya Ihara Takeshi Sato Takahiko Mitsui |
| author_sort | Midori Hara |
| collection | DOAJ |
| description | Neuroendocrine prostate cancer (NEPC) is rare, with short overall survival, and no established standard therapy. Therefore, the management of NEPC is often challenging. We report a case of a 63-year-old male diagnosed with NEPC and treated with multimodal examinations and therapies. Chemotherapy of cisplatin and etoposide for 6 months had a certain effect. However, his cancer progressed, and he took genetic screening exams. It revealed that his tumor mutational burden was high, and pembrolizumab was started. In this report, we suggested several new treatments. |
| first_indexed | 2024-04-13T09:38:31Z |
| format | Article |
| id | doaj.art-102f1d91b3fa4cafad957da91b1a20a6 |
| institution | Directory Open Access Journal |
| issn | 2214-4420 |
| language | English |
| last_indexed | 2024-04-13T09:38:31Z |
| publishDate | 2022-09-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Urology Case Reports |
| spelling | doaj.art-102f1d91b3fa4cafad957da91b1a20a62022-12-22T02:52:00ZengElsevierUrology Case Reports2214-44202022-09-0144102158Neuroendocrine prostate cancer treated with multimodal examination and therapy: A case reportMidori Hara0Satoru Kira1Manabu Kamiyama2Tatsuya Ihara3Takeshi Sato4Takahiko Mitsui5Department of Urology, University of Yamanashi Graduate School of Medical Sciences, Chuo-city, Yamanashi, JapanDepartment of Urology, University of Yamanashi Graduate School of Medical Sciences, Chuo-city, Yamanashi, Japan; Corresponding author Department of Urology, University of Yamanashi Graduate School of Medical Sciences, 1110 Shimokato, Chuo-city, Yamanashi, 409-3898, Japan.Department of Urology, Toranomon Hospital Kajigaya, Tokyo, JapanDepartment of Urology, University of Yamanashi Graduate School of Medical Sciences, Chuo-city, Yamanashi, JapanDepartment of Urology, Fujiyoshida Municipal Hospital, Fujiyoshida-city, Yamanashi, JapanDepartment of Urology, University of Yamanashi Graduate School of Medical Sciences, Chuo-city, Yamanashi, JapanNeuroendocrine prostate cancer (NEPC) is rare, with short overall survival, and no established standard therapy. Therefore, the management of NEPC is often challenging. We report a case of a 63-year-old male diagnosed with NEPC and treated with multimodal examinations and therapies. Chemotherapy of cisplatin and etoposide for 6 months had a certain effect. However, his cancer progressed, and he took genetic screening exams. It revealed that his tumor mutational burden was high, and pembrolizumab was started. In this report, we suggested several new treatments.http://www.sciencedirect.com/science/article/pii/S221444202200170XNeuroendocrine prostate cancerTumor mutational burden highPeptide receptor radionuclide therapy |
| spellingShingle | Midori Hara Satoru Kira Manabu Kamiyama Tatsuya Ihara Takeshi Sato Takahiko Mitsui Neuroendocrine prostate cancer treated with multimodal examination and therapy: A case report Urology Case Reports Neuroendocrine prostate cancer Tumor mutational burden high Peptide receptor radionuclide therapy |
| title | Neuroendocrine prostate cancer treated with multimodal examination and therapy: A case report |
| title_full | Neuroendocrine prostate cancer treated with multimodal examination and therapy: A case report |
| title_fullStr | Neuroendocrine prostate cancer treated with multimodal examination and therapy: A case report |
| title_full_unstemmed | Neuroendocrine prostate cancer treated with multimodal examination and therapy: A case report |
| title_short | Neuroendocrine prostate cancer treated with multimodal examination and therapy: A case report |
| title_sort | neuroendocrine prostate cancer treated with multimodal examination and therapy a case report |
| topic | Neuroendocrine prostate cancer Tumor mutational burden high Peptide receptor radionuclide therapy |
| url | http://www.sciencedirect.com/science/article/pii/S221444202200170X |
| work_keys_str_mv | AT midorihara neuroendocrineprostatecancertreatedwithmultimodalexaminationandtherapyacasereport AT satorukira neuroendocrineprostatecancertreatedwithmultimodalexaminationandtherapyacasereport AT manabukamiyama neuroendocrineprostatecancertreatedwithmultimodalexaminationandtherapyacasereport AT tatsuyaihara neuroendocrineprostatecancertreatedwithmultimodalexaminationandtherapyacasereport AT takeshisato neuroendocrineprostatecancertreatedwithmultimodalexaminationandtherapyacasereport AT takahikomitsui neuroendocrineprostatecancertreatedwithmultimodalexaminationandtherapyacasereport |